sls stock: trending now
17-11-2026
SLS Stock: Trending Now Following Pivotal Phase 3 Leukemia Trial Win
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) stock is surging in high-volume trading after the late-stage clinical biopharmaceutical company announced positive topline data from its pivotal Phase 3 REGAL trial. Following the announcement, SLS stock skyrocketed more than 235%, reaching a new 52-week high of $24.17 before trading around $22.71.
Why SLS Stock Is Moving Today
The massive rally in SELLAS Life Sciences shares is driven by clinical validation of its lead immunotherapeutic cancer vaccine, galinpepimut-S (GPS), in patients with acute myeloid leukemia (AML):
Primary Endpoint Met: The Phase 3 REGAL study achieved its primary overall survival (OS) endpoint, demonstrating both statistically significant and clinically meaningful survival improvements.
Survival & Risk Reduction Data: Patients treated with GPS achieved a median overall survival of 24.0 months compared to 14.7 months for those receiving the best available treatment, representing a 41% reduction in the risk of death.
Financial Runway: The clinical milestone follows SELLAS Life Sciences’ Q3 2026 financial update, in which the company reported a cash position of $134.7 millionbolstered by warrant exercisesto support ongoing late-stage development and regulatory preparations.
TradingView
SLS Stock Outlook and Pipeline Catalysts
With pivotal Phase 3 REGAL data in hand, investor focus shifts toward potential Biologics License Application (BLA) regulatory filings for galinpepimut-S. Alongside GPS, SELLAS continues to advance SLS009, its selective CDK9 inhibitor, which recently demonstrated encouraging response rates in high-risk AML trials ahead of presentations at the 2026 American Society of Hematology (ASH) annual meeting. Due to heightened retail and institutional momentum, SLS stock remains subject to elevated intraday volatility as the market digests the commercial potential of its oncology pipeline.
TradingView